Recent News

• 03.18.2026 - Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
• 03.18.2026 - Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
• 03.17.2026 - Akari Therapeutics Announces ADS Ratio Change
• 03.17.2026 - Akari Therapeutics Announces ADS Ratio Change
• 03.13.2026 - Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
• 03.13.2026 - Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
• 02.26.2026 - Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
• 02.26.2026 - Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
• 02.23.2026 - Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
• 02.23.2026 - Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

Recent Filings

• 03.17.2026 - EX-99.1 EX-99.1
• 03.17.2026 - 8-K Current report
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.04.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.04.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.02.2026 - 8-K Current report